No connection

Search Results

FONR vs IPHA

FONR
FONAR Corporation
NEUTRAL
Price
$18.61
Market Cap
$117.3M
Sector
Healthcare
AI Confidence
75%
IPHA
Innate Pharma S.A.
BEARISH
Price
$1.41
Market Cap
$132.2M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
FONR
16.18
IPHA
--
Forward P/E
FONR
--
IPHA
-2.25
P/B Ratio
FONR
0.69
IPHA
-5.18
P/S Ratio
FONR
1.11
IPHA
14.69
EV/EBITDA
FONR
6.29
IPHA
-2.29

Profitability

Gross Margin
FONR
40.8%
IPHA
0.0%
Operating Margin
FONR
11.74%
IPHA
-689.55%
Profit Margin
FONR
7.12%
IPHA
0.0%
ROE
FONR
6.01%
IPHA
--
ROA
FONR
3.16%
IPHA
-38.85%

Growth

Revenue Growth
FONR
2.4%
IPHA
-46.7%
Earnings Growth
FONR
1.1%
IPHA
--

Financial Health

Debt/Equity
FONR
0.24
IPHA
--
Current Ratio
FONR
10.0
IPHA
1.27
Quick Ratio
FONR
9.66
IPHA
1.14

Dividends

Dividend Yield
FONR
--
IPHA
--
Payout Ratio
FONR
0.0%
IPHA
0.0%

AI Verdict

FONR NEUTRAL

FONR presents as a classic value play with a stable Piotroski F-Score of 4/9 and a current price ($18.61) trading significantly below its Graham Number ($26.43). The company maintains an exceptionally strong balance sheet with a Current Ratio of 10.00 and very low debt (D/E 0.24), providing a massive safety cushion. However, this financial stability is offset by stagnant growth metrics, with YoY earnings growth of only 1.10%, and a bearish technical trend (10/100). Ultimately, the stock appears to be a low-risk, low-reward 'value trap' unless a growth catalyst emerges.

Strengths
Exceptional liquidity with a Current Ratio of 10.00
Very low leverage (Debt/Equity of 0.24)
Trading at a discount to book value (P/B 0.69)
Risks
Stagnant growth (Revenue growth of only 2.40% YoY)
Bearish technical trend (10/100 score)
Low insider sentiment (40/100)
IPHA BEARISH

IPHA exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a negative Price-to-Book ratio of -5.18, indicating negative shareholder equity. The company is experiencing a collapse in top-line growth with revenue declining 46.7% YoY, coupled with an unsustainable operating margin of -689.55%. While analysts maintain a 'strong_buy' rating with a $6.00 target, this is fundamentally disconnected from the current data-driven trajectory of value destruction and operational losses.

Strengths
Strong analyst consensus (Strong Buy) suggesting potential pipeline value not captured in financials
Current ratio of 1.27 provides a minimal short-term liquidity cushion
Recent slight 1-week price recovery (+2.9%)
Risks
Negative Book Value (P/B -5.18) indicating insolvency or severe capital erosion
Catastrophic operating margins (-689.55%)
Significant revenue contraction (-46.7% YoY)

Compare Another Pair

FONR vs IPHA: Head-to-Head Comparison

This page compares FONAR Corporation (FONR) and Innate Pharma S.A. (IPHA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile